vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Borealis Foods Inc. (BRLS). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $7.1M, roughly 1.5× Borealis Foods Inc.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -53.2%, a 76.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -12.0%). Over the past eight quarters, Borealis Foods Inc.'s revenue compounded faster (-2.4% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Borealis Foods Inc is a food technology enterprise specializing in developing and producing high-quality plant-based protein products including plant-based meat alternatives. It mainly serves retail and food service customers across North America and Europe, focusing on delivering affordable, nutritious sustainable food options matching the taste of conventional animal-derived meat.
ABUS vs BRLS — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $7.1M |
| Net Profit | $2.5M | $-3.8M |
| Gross Margin | — | 14.6% |
| Operating Margin | 13.9% | -27.1% |
| Net Margin | 23.5% | -53.2% |
| Revenue YoY | 522.2% | -12.0% |
| Net Profit YoY | 112.7% | 21.8% |
| EPS (diluted) | $0.01 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $7.1M | ||
| Q2 25 | $10.7M | $7.2M | ||
| Q1 25 | — | $6.8M | ||
| Q4 24 | — | $6.8M | ||
| Q3 24 | — | $8.1M | ||
| Q2 24 | — | $5.5M | ||
| Q1 24 | — | $7.9M | ||
| Q4 23 | $2.1M | $7.5M |
| Q3 25 | — | $-3.8M | ||
| Q2 25 | $2.5M | $-4.6M | ||
| Q1 25 | — | $-4.2M | ||
| Q4 24 | — | $-5.8M | ||
| Q3 24 | — | $-4.8M | ||
| Q2 24 | — | $-6.3M | ||
| Q1 24 | — | $-8.4M | ||
| Q4 23 | — | $-6.7M |
| Q3 25 | — | 14.6% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 13.1% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | — | 15.8% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 3.1% | ||
| Q4 23 | — | 7.5% |
| Q3 25 | — | -27.1% | ||
| Q2 25 | 13.9% | -46.7% | ||
| Q1 25 | — | -42.6% | ||
| Q4 24 | — | -68.4% | ||
| Q3 24 | — | -44.8% | ||
| Q2 24 | — | -94.8% | ||
| Q1 24 | — | -88.3% | ||
| Q4 23 | -967.2% | -60.5% |
| Q3 25 | — | -53.2% | ||
| Q2 25 | 23.5% | -64.0% | ||
| Q1 25 | — | -61.2% | ||
| Q4 24 | — | -85.3% | ||
| Q3 24 | — | -59.8% | ||
| Q2 24 | — | -115.0% | ||
| Q1 24 | — | -106.8% | ||
| Q4 23 | — | -89.3% |
| Q3 25 | — | $-0.18 | ||
| Q2 25 | $0.01 | $0.21 | ||
| Q1 25 | — | $-0.20 | ||
| Q4 24 | — | $-0.82 | ||
| Q3 24 | — | $-0.23 | ||
| Q2 24 | — | $0.29 | ||
| Q1 24 | — | $-0.49 | ||
| Q4 23 | $-0.12 | $-0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | — |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $-12.9M |
| Total Assets | $103.3M | $56.3M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | $37.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $126.0M | — |
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $0 | — |
| Q3 25 | — | $-12.9M | ||
| Q2 25 | $83.0M | $-9.2M | ||
| Q1 25 | — | $-4.8M | ||
| Q4 24 | — | $-695.9K | ||
| Q3 24 | — | $5.1M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $16.2M | ||
| Q4 23 | $106.0M | $-21.3M |
| Q3 25 | — | $56.3M | ||
| Q2 25 | $103.3M | $57.3M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $61.9M | ||
| Q2 24 | — | $63.6M | ||
| Q1 24 | — | $70.3M | ||
| Q4 23 | $144.4M | $65.8M |
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-190.6K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-190.6K | ||
| Q2 25 | $-15.7M | $-2.2M | ||
| Q1 25 | — | $-1.4M | ||
| Q4 24 | — | $-819.4K | ||
| Q3 24 | — | $-3.3M | ||
| Q2 24 | — | $-4.2M | ||
| Q1 24 | — | $-6.8M | ||
| Q4 23 | $-17.3M | $-1.9M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-1.4M | ||
| Q4 24 | — | $-951.6K | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-4.7M | ||
| Q1 24 | — | $-7.3M | ||
| Q4 23 | — | $-2.9M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -20.3% | ||
| Q4 24 | — | -14.1% | ||
| Q3 24 | — | -46.1% | ||
| Q2 24 | — | -86.7% | ||
| Q1 24 | — | -92.7% | ||
| Q4 23 | — | -38.9% |
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | — | 5.6% | ||
| Q2 24 | — | 9.4% | ||
| Q1 24 | — | 7.0% | ||
| Q4 23 | 0.0% | 12.7% |
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
